Winning XOMA Stock Forecast: Xoma Corporation Jumped Up By 269.14% in 1 Year
“We made significant progress on multiple fronts executing our new business strategy, and in doing so we completely transformed the Company. The highlight events were clearly the license agreements we secured for both gevokizumab and our IL-1 beta intellectual property portfolio with Novartis. Our strategy was further reinforced with new license agreements for use of our proprietary phage display libraries for antibody discovery.”
– Jim Neal, Chief Executive Officer of XOMA
Over the last 12 months
